2024
Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review
Patel K, Rathod K, Lansky A, Prendergast B, Kharbanda R, Mathur A, Perry R, Baumbach A. Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review. Stroke 2024, 55: 2754-2764. PMID: 39371005, DOI: 10.1161/strokeaha.124.047149.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementAortic valve replacementCerebrovascular eventsValve replacementAtrial fibrillationLow operative risk patientsAdvent of transcatheter aortic valve replacementNew-onset atrial fibrillationComplication of transcatheter aortic valve replacementIncreased risk of bleedingHigher risk of cerebrovascular eventsAssociated with significant mortalityTranscatheter aortic valve replacement procedureRisk of cerebrovascular eventsOperative risk patientsResults of embolizationRisk of bleedingRisk of thromboembolismHypoattenuated leaflet thickeningImprove risk stratificationCerebral lesion volumeAssociated with cerebrovascular eventsTherapy to patientsOverall stroke rateSeverity of comorbiditiesApproval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story
Goldsweig A, Deng Y, Yao X, Desai N, Cohen D, Aronow H, Messé S, Ross J, Lansky A, Savitz S. Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010200. PMID: 38189127, PMCID: PMC10844981, DOI: 10.1161/circoutcomes.123.010200.Peer-Reviewed Original ResearchStroke/systemic embolismTransient ischemia attackPFO closureSystemic embolismIschemia attackRetrospective cohort studyTransient ischemic attackHalf of patientsOptumLabs Data WarehouseCommercial insurance enrolleesRegulatory approvalClinical trial publicationsIschemic attackRecurrent strokeCohort studyPatent foramenUnderwent closureAtrial fibrillationClinical trialsInsurance enrolleesDecompression illnessTrial publicationsOff labelPatientsProcedure volume
2023
Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study
Grubman D, Ahmad Y, Leipsic J, Blanke P, Pasupati S, Webster M, Nazif T, Parise H, Lansky A. Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study. The American Journal Of Cardiology 2023, 207: 28-34. PMID: 37722198, DOI: 10.1016/j.amjcard.2023.08.137.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementAtrial fibrillationHuman studiesEmbolic protection device useHigh embolic riskPrimary end pointHigh-risk patientsIndependent core laboratorySelf-expanding valvesComputed tomography angiographyProtection device useCerebral embolizationCerebrovascular eventsEmbolic riskAcute thrombusEmbolic burdenAngiography featuresTechnical successTomography angiographyEmbolic debrisValve useCore laboratoryEnd pointEffect of antecedent statin usage on conduction disturbances and arrhythmias after transcatheter aortic valve replacement
Shah T, Maarek R, See C, Huang H, Wang Y, Parise H, Forrest J, Lansky A. Effect of antecedent statin usage on conduction disturbances and arrhythmias after transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine 2023, 59: 3-8. PMID: 37573173, DOI: 10.1016/j.carrev.2023.07.022.Peer-Reviewed Original ResearchConceptsAtrial fibrillationConduction disturbancesPrimary endpointStatin usersPacemaker placementRate of AFTranscatheter aortic valve replacementNew atrial fibrillationNew conduction disturbancesPersistent conduction disturbancesAortic valve replacementLong-term prognosisSmall retrospective studiesSignificant differencesPrior pacemakerIndex hospitalizationIntensity statinsValve replacementConsecutive patientsPropensity matchingProcedural complicationsStatin regimenRetrospective studyStatin usageCardiac procedures
2021
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations
Vrachatis DA, Papathanasiou KA, Iliodromitis KE, Giotaki SG, Kossyvakis C, Raisakis K, Kaoukis A, Lambadiari V, Avramides D, Reimers B, Stefanini GG, Cleman M, Giannopoulos G, Lansky A, Deftereos SG. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs 2021, 81: 1381-1395. PMID: 34297330, DOI: 10.1007/s40265-021-01565-3.Peer-Reviewed Original ResearchConceptsAtrial fibrillationSGLT2 inhibitorsCardiorenal protectionAntiarrhythmic effectsClinical dataSodium/glucose co-transporter-2 inhibitorClinical data implyDate available evidenceGlucose-lowering medicationsEffective therapeutic optionPotential pathophysiological linkLarge clinical trialsPre-specified endpointsType 2 diabetesPossible beneficial effectsPost Hoc AnalysisNormoglycemic adultsAF burdenAF preventionPathophysiologic mechanismsPathophysiological linkSGLT2 inhibitionAntiarrhythmic potentialSodium glucoseTherapeutic optionsAtrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence
Vrachatis DA, Papathanasiou KA, Kossyvakis C, Giotaki SG, Raisakis K, Iliodromitis KE, Reimers B, Stefanini GG, Cleman M, Sianos G, Lansky A, Deftereos SG, Giannopoulos G. Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence. Diabetes Research And Clinical Practice 2021, 174: 108724. PMID: 33647332, DOI: 10.1016/j.diabres.2021.108724.Peer-Reviewed Original ResearchConceptsDiabetes mellitusAtrial fibrillationType 1 diabetes mellitusIndependent risk factorAtrial fibrillation managementAtrial fibrillation riskAF developmentInsulin deficiencyGlycemic variabilityRisk factorsClinical dataClinical studiesMicrovascular sequelaeAtrial arrhythmogenesisAnimal studiesAtrial myocytesClinical practiceArrhythmia initiationStructural remodelingClinical implicationsT1DMOxidative stressPI3KGlucose transportationMellitus
2013
Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis
Wolfrum M, Froehlich GM, Knapp G, Casaubon LK, DiNicolantonio JJ, Lansky AJ, Meier P. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. Heart 2013, 100: 389. PMID: 23793373, DOI: 10.1136/heartjnl-2013-304394.Peer-Reviewed Original ResearchConceptsBest medical therapyPatent foramen ovalPercutaneous PFO closurePFO closureCryptogenic strokePercutaneous closureMedical therapyAtrial fibrillationRelative riskSystematic reviewNew-onset atrial fibrillationOnset atrial fibrillationPooled relative riskRisk of bleedingPatent foramen ovaleMain end pointSignificant risk reductionRandom-effects modelStroke preventionMultivariate adjustmentSecondary preventionForamen ovaleClosure groupClinical trialsSignificant treatment effect